COVID-19 and liver diseases,what we know so far  

作　　者：Mohamed Elnaggar Ahmed Abomhya Ismail Elkhattib Nabila Dawoud Rajkumar Doshi 

机构地区：[1]Department of Internal Medicine,University of Nevada Reno School of Medicine,Reno,NV 89052,United States [2]Department of Internal Medicine,The Brooklyn Hospital Center,Brooklyn,NY 11200,United States [3]Department of Internal Medicine,University of Connecticut,Farmington,CT 06030,United States [4]Department of Internal Medicine,University of Kentucky,Lexington,KY 40508,United States [5]Department of Cardiology,St Joseph's University Medical Center,Paterson,NJ 07503,United States

出　　处：《World Journal of Clinical Cases》2022年第13期3969-3980,共12页世界临床病例杂志

摘　　要：Coronavirus disease 2019(COVID-19)pneumonia outbreak started in December 2019.On March 12,2020,the World Health Organization(WHO)declared that the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)constitutes a pandemic,and as of May 2021,SARS-CoV-2 has infected over 167.3 million patients,including 3.4 million deaths,reported to WHO.In this review,we will focus on the relationship between SARS-CoV-2 infection and the liver.We will discuss how chronic liver diseases affect the COVID-19 disease course and outcomes.We will also discuss the SARS-CoV-2 effects on the liver,mechanisms of acute liver injury,and potential management plans.

关 键 词：COIVD-19 SARS-CoV-2 Liver diseases TRANSAMINASES Non alcoholic fatty liver Hepatocellular carcinoma 

分 类 号：R563.1[医药卫生—呼吸系统] R575[医药卫生—内科学]